On May 28, 2021, Amgen announced that the FDA had approved LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

LUMAKRAS had received accelerated approval based on overall response rate and duration of response.